Clinical trials: Anlotinib
NSCLC (Non-small Cell Lung Cancer), EGFR
Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC
Exploring the efficacy and safety of firmonertinib combined with anlotinib and platinum-based doublet chemotherapy as neoadjuvant therapy in patients with EGFR-mutant resectable NSCLC
- Conditions
- NSCLC (Non-small Cell Lung Cancer), EGFR, Neoadjuvant Therapy
- Trial name
- NCT07807722
- Testing
- Firmonertinib combined anlotinib and chemotehrapy
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Hubei Cancer Hospital
Hepatocellular Cancer
Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib
PD-1 inhibitors have become the standard treatment for advanced hepatocellular cancer, while targeted drugs such as sorafenib and lenvatinib are the first-line standard treatment for hepatocellular cancer.
- Trial name
- NCT05453383
- Testing
- Anlotinib;Toripalimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shen Feng
Colorectal Cancer
A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.
This is a Phase Ib clinical study to evaluate the efficacy and safety of TQB2618 injection as monotherapy and a combination regimen (with Penpulimab injection ± Anlotinib hydrochloride capsules) in the treatment of advanced…
- Trial name
- NCT06010901
- Testing
- TQB2618 injection, Penpulimab injection, Anlotinib hydrochloride capsules
- Where
- 15 sites in China
- Volunteers
- 75 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Biliary Tract Cancer
Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer
To evaluate the efficacy and safety of Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin Compared With Gemcitabine +Cisplatin as First-line Chemotherapy for Unresectable or Metastatic Biliary Tract…
- Trial name
- NCT04300959
- Testing
- Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin, Gemcitabine Plus(+)Cisplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Zhejiang Cancer Hospital
Sarcoma, Soft Tissue
Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients
Anlotinib is a multi-target receptor tyrosine kinase inhibitor. It can inhibit the angiogenesis related kinase, such as Vascular Endothelial Growth Factor Receptor (VEGFR), Fibroblast Growth Factor Receptor(FGFR)…
- Trial name
- ALTER-S005 (NCT03815474)
- Testing
- anlotinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Esophageal Cancer
Anlotinib Combined With PD-1 Inhibitors for Advanced/Metastatic Esophageal Cancer
Efficacy and Safety of Anlotinib combined with PD-1 inhibitors as 2 or more lines treatment for Heavily Pretreated Patients With Advanced, Metastatic Squamous Cell Carcinoma of the Esophagus.
- Trial name
- APEC (NCT04984096)
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Advanced Biliary Cancer
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer
This study is a randomized, parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus chemotherapy as second-line treatment in subjects with advanced…
- Trial name
- NCT04809142
- Testing
- TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection
- Where
- 17 sites in China
- Volunteers
- 392 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nasopharyngeal Neoplasms
Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma
First-diagnosed metastasis or recurrence/metastasis NPC Patients will be treated with anlotinib, penpulimab and capecitabine.
- Trial name
- ALTER-HN005 (NCT05807880)
- Testing
- The combination treatment of anlotinib, penpulimab and capecitabine.
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Sun Yat-sen University
Small Cell Lung Cancer
Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit…
- Trial name
- NCT05001971
- Testing
- Anlotinib Plus Penpulimab
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Hunan Cancer Hospital
Advanced Head, Neck and Chest Cancer
A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer
AK105 is a humanized monoclonal antibody that specially binds to PD-1. Anlotinib is a small molecule tyrosine kinase inhibitor. Based on the mechanism study, tumor vascular abnormalities promote tissue hypoxia and increase lactic…
- Trial name
- NCT04203719
- Testing
- AK105, Anlotinib
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit…
- Trial name
- ACDFNSNSCLC (NCT03750916)
- Testing
- Anlotinib Hydrochloride plus Docetaxel
- Volunteers
- 46 people
- Sponsor
- Qilu Hospital of Shandong University
Endometrial Carcinoma
A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma
A clinical trial to evaluate TQB2858 injection combined with Anlotinib Hydrochloride capsule in the treatment of recurrent or metastatic advanced endometrial carcinoma
- Trial name
- NCT05121363
- Testing
- TQB2858 injection, Anlotinib Hydrochloride capsules
- Where
- 2 sites in China
- Volunteers
- 113 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Clear Cell Sarcoma (CCS)
Vebreltinib for Advanced or Metastatic CCS
This is a prospective, cohort, multicenter study. Cohort 1 is treatment group. All eligible subjects will receive Vebreltinib (200 mg bid po) after signing the informed consent and meeting the inclusion/exclusion criteria, until…
- Trial name
- NCT07153887
- Testing
- Vebreltinib, Standard medical treatment
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Non Clear Cell Renal Carcinoma
Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
The combination of immune checkpoint inhibitors (ICIs) plus angiogenesis inhibitors has demonstrated significant anti-tumor activity in certain cancer.
- Trial name
- NCT05220267
- Testing
- Anlotinib plus Sintilimab
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer, Brain Metastases
the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer
Subject population：Patients with brain metastases from EGFR mutation-positive non-small cell lung cancer who have not received systemic treatment. Experimental design: Single-center, single-arm phase II clinical trial.
- Trial name
- NCT04978753
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Li-kun Chen
SCLC, Extensive Stage
Lomustine Combined With Anlotinib as Interventional Therapy for Extensive-stage Small Cell Lung Cancer Resistant to Second-line and Above Treatment
This single-arm phase II study aims to evaluate the efficacy and safety of lomustine combined with anlotinib in patients with extensive-stage small cell lung cancer resistant to second-line and above systemic treatment.
- Trial name
- Aurora003 (NCT07632209)
- Testing
- Lomustine, Anlotinib
- Volunteers
- 46 people
- Sponsor
- Yayi He
Small Cell Lung Cancer
Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer
Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor-associated kinases involved in cell proliferation such as…
- Trial name
- NCT04073550
- Testing
- Anlotinib, Topotecan
- Where
- 2 sites in China
- Volunteers
- 184 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
A Trial of Anlotinib Combined With Docetaxel in EGFR Mutations Advanced Non Small Cell Lung Cancer Patients
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit angiogenesis-related kinases, such as VEGFR, FGFR, PDGFR and tumor cell proliferation related kinase c-Kit…
- Trial name
- NCT04619563
- Testing
- Anlotinib Hydrochloride plus Docetaxel
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Shandong Cancer Hospital and Institute
Breast Cancer
Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients
vinorelbine are one of the main chemotherapy drugs used in the treatment of advanced breast cancer. It is available in oral form, making it convenient to use and an ideal choice for rhythmic chemotherapy.
- Trial name
- NCT06015126
- Testing
- metronomic oral vinorelbine plus anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Yan Xue
NSCLC
A Trial of AK104 Plus Anlotinib in NSCLC
This trial is a single arm, two cohorts, phase Ib/II study. All patients are stage IIIB/C or IV NSCLC, Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT04646330
- Testing
- AK104+anlotinib
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Akeso